Tumor fraction-guided cell-free DNA profiling in metastatic solid tumor patients

Tumor fraction-guided cell-free DNA profiling in metastatic solid tumor patients

Abstract Background Cell-free DNA (cfDNA) profiling is increasingly used to guide cancer care, yet mutations are not always identified. The ability to detect somatic mutations in plasma depends on both assay sensitivity and the fraction of circulating DNA in plasma that is tumor-derived (i.e., cfDNA...

Full description

Bibliographic Details
Main Authors: Dana W. Y. Tsui, Michael L. Cheng, Maha Shady, Julie L. Yang, Dennis Stephens, Helen Won, Preethi Srinivasan, Kety Huberman, Fanli Meng, Xiaohong Jing, Juber Patel, Maysun Hasan, Ian Johnson, Erika Gedvilaite, Brian Houck-Loomis, Nicholas D. Socci, S. Duygu Selcuklu, Venkatraman E. Seshan, Hongxin Zhang, Debyani Chakravarty, Ahmet Zehir, Ryma Benayed, Maria Arcila, Marc Ladanyi, Samuel A. Funt, Darren R. Feldman, Bob T. Li, Pedram Razavi, Jonathan Rosenberg, Dean Bajorin, Gopa Iyer, Wassim Abida, Howard I. Scher, Dana Rathkopf, Agnes Viale, Michael F. Berger, David B. Solit
Format: Article
Language:English
Published: BMC 2021-05-01
Series:Genome Medicine
Subjects:
Liquid biopsy
Plasma DNA
Molecular diagnostic
Cancer
Sequencing
Noninvasive
Online Access:https://doi.org/10.1186/s13073-021-00898-8

Internet

https://doi.org/10.1186/s13073-021-00898-8

Similar Items